SCHEMBL490696

SCHEMBL490696

CC(C)(C)OC(=O)N[C@H](CCO[Si](C)(C)C(C)(C)C)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 7/20 0.43
CTSS P25774 5/20 0.43
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
PPARA Q07869 7/20 0.41
PPARG P37231 6/20 0.41
ITGAV P06756 1/20 0.40
ITGB6 P18564 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
ACE P12821 1/20 0.40
PPARD Q03181 2/20 0.39
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191310 1.00 CTSK (0.43) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL191311 1.00 CTSK (0.43) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL28821394 0.92 CTSK (0.45) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL28821396 0.92 CTSK (0.45) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL29548094 0.90 CTSK (0.41) CTSKCTSSITGB3ITGA2BMEN1
SCHEMBL26968991 0.90 CTSK (0.41) CTSKCTSSITGB3ITGA2BMEN1
SCHEMBL19080575 0.89 CTSK (0.40) CTSKCTSSITGB3ITGA2BCTSL
SCHEMBL865794 0.88 FOLH1 (0.35) CTSKCTSSITGB3ITGA2BITGAV
SCHEMBL865793 0.88 FOLH1 (0.35) CTSKCTSSITGB3ITGA2BITGAV
SCHEMBL23177271 0.87 CTSK (0.42) CTSKCTSSITGB3ITGA2BCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122160-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2025-04-17 US disclosed
CN-116829555-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2023-09-29 CN disclosed
EP-4211122-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2023-07-19 EP disclosed
WO-2022056281-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2022-03-17 WO disclosed
US-8106091-B2 Inhibitors of IKK-beta serine-threonine protein kinase CHROMA THERAPEUTICS LTD. (GB) 2012-01-31 US disclosed
US-8106091-B2 Inhibitors of IKK-beta serine-threonine protein kinase CHROMA THERAPEUTICS LTD. (GB) 2012-01-31 US disclosed
EP-2086956-B1 INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE CHROMA THERAPEUTICS LTD (GB) 2011-09-14 EP disclosed
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase CHROMA THERAPEUTICS LTD. (GB) 2010-03-18 US disclosed
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase CHROMA THERAPEUTICS LTD. (GB) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase IKBKB, IKBKE, CHUK CTSK 2888/4885CTSS 2844/4885ITGB3 2310/4885
US-20250122160-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN1, PTPN2, PTPN18 CTSK 3003/4885CTSS 3337/4885ITGB3 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.